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Abstract The mechanisms of oxidative stress in schizo-
phrenic patients are not fully understood. In the present
study, we investigated the effect of elevated level of homo-
cysteine (Hcys) on some parameters of oxidative stress,
namely thiobarbituric acid reactive substances (TBARS), an
index of lipid peroxidation in plasma, the level of carbonyl
groups in plasma proteins, as well as the amount of 3-ni-
trotyrosine in plasma proteins isolated from schizophrenic
patients. Patients hospitalised in I and II Psychiatric
Department of Medical University in Lodz, Poland were
interviewed with special questionnaire (treatment, course of
diseases, dyskinesis and other EPS). According to DSM-IV
criteria all patients had diagnosis of paranoid type. They
were treated with antipsychotic drugs (clozapine, risperi-
done, olanzapine). Mean time of schizophrenia duration was
about 5 years. High-performance liquid chromatography
was used to analyse the total level of homocysteine in
plasma. Levels of carbonyl groups and 3-nitrotyrosine resi-
dues in plasma proteins were measured by ELISA and a
competition ELISA, respectively. The lipid peroxidation in
plasma was measured by the level of TBARS. Our results
showed that in schizophrenic patients the amount of homo-
cysteine in plasma was higher in comparison with the control
group. We also observed a statistically increased level of
biomarkers of oxidative/nitrative stress such as carbonyl
groups or 3-nitrotyrosine in plasma proteins from schizo-
phrenic patients. Moreover, our experiments indicate that the
correlation between the increased amount of homocysteine
and the oxidative stress exists. Considering the data pre-
sented in this study, we suggest that the elevated Hcys in
schizophrenic patients may stimulate the oxidative stress.
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Introduction
In schizophrenic patients dysregulation of reactive oxygen
species (ROS) and reactive nitrogen species (RNS)
metabolism, as detected by abnormal activities of critical
antioxidant enzymes and other indicators—lipid peroxi-
dation in plasma, red blood cells, blood platelets, and
cerebrospinal fluid is observed [1–3]. Such abnormalities
have been associated with tardive dyskinesia, negative
symptoms, neurological signs and poor premorbid func-
tion. Li et al. [4] also suggest that excess ROS formation
may play a critical role in the etiology of schizophrenia. A
cell membrane dysfunction caused by lipid peroxidation
can be secondary to a free radical–mediated pathology and
may contribute to specific aspects of schizophrenic
symptomatology and complications of its treatment. Our
earlier studies by using different specific biomarkers of
oxidative stress, including activity of platelet antioxidative
enzyme—superoxide dismutase (SOD) revealed that in
blood platelets from schizophrenic patients oxidative stress
occurs [3]. We have presented that suppressed SOD
activity in blood platelets from schizophrenic patients is
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associated with enhanced ROS generation and lipid per-
oxidation when compared with healthy control [3]. We
also observed, that the level of isoprostanes (indicators of
oxidative stress) in schizophrenic patients in acute period
of psychosis is extremely high compared with control
group [5], and our results indicate that in schizophrenic
patients increased production of isoprostanes reflects oxi-
dative stress and oxidative damage of lipids.
The modification of proteins plays an essential role in
the pathogenesis of various diseases, including vascular
complications, inflammatory and mental disorders. Our
earlier results showed that the level of biomarkers of
oxidation/nitration proteins in plasma of schizophrenic
patients (in acute period of psychosis) is distinctly higher
than in plasma of healthy subjects [6]. Moreover, in
schizophrenic patients reduced status of plasma total
antioxidant capacity was observed [7]. Our earlier results
reported the changes of the level of low-molecular-weight
thiols such as glutathione, cysteine and cysteinylglycine
(which are physiological free radical scavengers) in
plasma from schizophrenic patients, whereas the level of
homocysteine (Hcys) was significantly elevated in plasma
of schizophrenic patients in acute period of psychosis [6].
Because on the basis of various observations, it is pro-
posed that Hcys may act as an oxidant in the model
system in vitro and in vivo [8, 9], the aim of our present
study was to explain the effect of the elevated Hcys on
the selected parameters of oxidative stress (carbonyl
groups and 3-nitrotyrosine levels in proteins and thio-
barbituric acid reactive substances (TBARS)—a bio-
marker of lipid peroxidation) of plasma from schizo
phrenic patients. Oxidative/nitrative changes in proteins
include carbonyl groups formation and 3-nitrotyrosine
generation. Nitration of tyrosine residues by nitric
oxide—derived species results in the accumulation of
3-nitrotyrosine in proteins. Tyrosine nitration is also a
biomarker of oxidative damage induced by peroxynitrite.
Other protein modification mediated by free radical is
protein carbonylation, which is a non enzymatic addition
of aldehydes or ketones to specific amino acid residues.
Materials and Methods
Materials
Sheep anti-nitrotyrosine polyclonal antibodies were from
Oxis (Portland, USA). Biotyninylated anti-goat/mouse/
rabbit antibody and streptavidin-biotynylated horseradish
peroxidase were from DAKO (Glostrup, Denmark). All
other reagents were of analytical grade and were provided
by commercial suppliers.
The Criteria of Schizophrenic Patients Inclusion
The studied population of schizophrenic patients com-
prised 19 patients between the ages of 25–36 years (mean
30, 4 ± 3.2) who were hospitalized in I and II Psychiatric
Department of Medical University in Lodz, Poland. All
subjects were interviewed with special questionnaire
(treatment, course of diseases, dyskinesis and other extra-
pyramidal syndromes) and according to DSM-IV criteria
[10] all patients had diagnosis of paranoid type. They were
treated with antipsychotic drugs (clozapine, risperidone,
olanzapine) during therapy. They did not use addictive
antidepressants or mood stabilizers. Mean time of schizo-
phrenia duration was 5 years. Table 1 present clinical
characteristics of patients with schizophrenia.
The Criteria of Volunteers Inclusion
Blood samples were taken from 19 healthy volunteers
(males and females) aged between 25 and 35 years (mean
30 ± 3.1). Blood samples were taken from healthy sub-
jects without psychiatric, neurological or somatic disor-
ders and history of head injuries, allergy and lipid or
carbohydrate metabolism disorders, untreated with drugs.
Healthy subjects did not use addictive substances and
antioxidant supplementation, their diet was balanced
(meat and vegetables), lived in similar socio-economic
conditions. Subjects with significant medical illness were
excluded.
Qualification Questionnaire
Structured medical interviews were carried out, consider-
ing both mental and physical status, medical history, ali-
mentary habits and substance use. The following exclusion
criteria were applied: any somatic disorders, especially
circulatory diseases, disorders of lipid metabolism and
diabetes, malnutrition and neurological diseases serious
head injuries mental disorders either in volunteers or their
Table 1 Clinical characteristics of patients with schizophrenia and
healthy volunteers subjects
Patients with
schizophrenia
(n = 19)
Control
subject
(n = 19)
Sex, M/F 11/8 15/4
Age (years) 30.4 ± 3.2 30.0 ± 3.1
Duration of illness (years) 8.4 ± 4.3 NS
PANSS 68.3 ± 13.6 NS
PANSS-positive symptom scores 11.2 ± 4.1 NS
PANSS-negative symptom scores 19.7 ± 5.8 NS
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families use of any medications or addictive substances,
unbalanced diet antioxidant supplementation psychiatric
examination (using the M.I.N.I.—Mini International Neu-
ropsychiatric Interview [11]) neurological and somatic
examinations. Laboratory tests: lipid panel (total choles-
terol, LDL, HDL, triglycerides) and glucose.
The protocol was passed by the Committee for Research
on Human Subjects of the Medical University of Lodz
number RNN/899/2000.
All patients and volunteers included in the study have
been informed about aims of the study and methods
implemented and expressed their written informed consent
for participation in this study.
Isolation of Plasma
Human blood from schizophrenic patients and healthy
volunteers was collected into sodium citrate (5 mM final
concentration) and immediately centrifuged (3,0009g,
15 min) to get plasma.
Evaluation of Lipid Peroxidation Level
Samples of plasma (from schizophrenic patients and
healthy volunteers) were transferred to an equal volume
of 20% (v/v) cold trichloroacetic acid in 0.6 M HCl and
centrifuged at 1,2009g for 15 min. One volume of clear
supernatant was mixed with 0.2 volume of 0.12 M thio-
barbituric acid in 0.26 M Tris at pH 7.0 and immersed in
a boiling water bath for 15 min. Absorbance at 532 nm
was measured and results were expressed as nmoles of
TBARS [12].
Determination of 3-Nitrotyrosine in the Plasma Proteins
by a C-ELISA Method
Detection of 3-nitrotyrosine-containing proteins by a com-
petition ELISA (C-ELISA) method in plasma (from
schizophrenic patients and healthy volunteers) was per-
formed according to the procedure of Khan et al. [13] as
described previously [14]. The nitro-fibrinogen (at concen-
tration of 0.5 lg/ml and 3–6 mol nitrotyrosine/mol protein)
was prepared for use in the standard curve. The linearity of
the C-ELISA method was confirmed by the construction of a
standard curve ranging from 10 to 500 nM nitrotyrosine-
fibrinogen equivalent. The concentrations of nitrated pro-
teins that inhibit anti-nitrotyrosine antibody binding were
estimated from the standard curve and are expressed as nitro-
Fg equivalents. The amount of nitrotyrosine present in
fibrinogen after treatment with peroxynitrite (at final con-
centration of 1 mM) was determined spectrophotometrically
(at pH 11.5, e430nm = 4,400 M
-1 cm-1).
Detection of Carbonyl Groups in the Plasma Proteins
by ELISA Method
Detection of carbonyl groups by ELISA method (using
anti-DNP antiobodies) in plasma (from schizophrenic
patients and healthy volunteers) was carried out according
to a method described by Buss et al. [15] as described
previously [14]. Human plasma proteins reacted with
dinitrotrophenylhydrazine (DNP) and then proteins were
non-specifically adsorbed to an ELISA plate. The perox-
ynitrite treated-fibrinogen (10 nmol of carbonyl groups/mg
of fibrinogen) was prepared for use in the standard curve.
The linearity of the ELISA method was confirmed by the
construction of a standard curve ranging form 0.1 to
10 nmol carbonyl groups/mg of fibrinogen. The amount
of carbonyl groups present in fibrinogen after treatment
with peroxynitrite (at final concentration of 1 mM) was
determined spectrophotometrically as described Levine
et al. [16].
Determination of Homocysteine in Plasma
The classical technique High-performance liquid chroma-
tography (HPLC) has been used to analysis of homocys-
teine from human plasma (from schizophrenic patients and
healthy volunteers). HPLC analysis was performed with a
Hewlett-Packard 1100 Series system according to
Głowacki et al. [17] and Bald et al. [18].
Statistical Analyses
All the values in this study were expressed as mean ± SD.
In order to eliminate uncertain data, Grubbs test was per-
formed. The statistically significant difference between the
control group and schizophrenic patients was done by
Mann–Whitney test using StatSoft Inc. ‘‘Statistica’’ v. 6.0.
Regression line was calculated by means of the least-
squares method.
Results
Using HPLC method we determined in human plasma the
levels of homocysteine. Our studies have shown that the
level of homocysteine in plasma from schizophrenic
patients was significantly higher (about 55%) than in
plasma obtained from healthy volunteers (Table 2). We
have also observed that the level of different biomarkers of
oxidative stress in plasma from schizophrenic patients
differs from their level in plasma obtained from healthy
volunteers (Table 2). The level of carbonyl groups (deter-
mined by ELISA method) in plasma proteins from
schizophrenic patients was significantly higher than the
Neurochem Res (2012) 37:1057–1062 1059
123
level of carbonylation in plasma obtained from healthy
volunteers (Table 2). In plasma proteins from schizo-
phrenic patients the amount of 3-nitrotyrosine as
determined by a competition C-ELISA method was also
higher than in control group (Table 2). We have observed
the same process when we measured the lipid peroxidation
(Table 2).
The correlation between the increased amount of Hcys
and changes in the level of various biomarkers of oxidative
stress in plasma from schizophrenic patients is presented in
Fig. 1.
Discussion
L-Homocysteine is an endogenous amino acid, containing
the free thiol group, which in healthy cells is involved in
methionine and cysteine synthesis/resynthesis. Indirectly,
Hcys participates in methyl, folate, and cellular thiols
metabolism [19]. Approximately 80% of total plasma Hcys
is protein bound, and only a small amount exists as a free
reduced Hcys (about 0.1 lM). The majority of the unbound
portion of Hcys is oxidized to form dimers (homocystine) or
combined with cysteine to form mixed disulphides [20, 21].
Elevated concentrations of homocysteine in human tissues,
definied as hyperhomocysteinemia have been correlated
with some diseases, such as cardiovascular, neurodegener-
ative, and kidney disorders. The elevated level of homo-
cysteine has been repeatedly observed in patients
with schizophrenia [6, 22–24]. Molecular-genetic studies
revealed tha association between schizophrenia and poly-
morphisms of two genes—methylenetetrahydrofolate
reductase and cystathionine-beta-synthase involved in the
conversion of homocysteine to methionine and cysteine,
respectively [23]. Haidemenos et al. [25] also observed that
patients in chronic schizophrenia had increased the amount
of plasma homocysteine compared to control, but this
increase in plasma homocysteine is not related to plasma
folate and vitamin B12 levels. In the Tunisian population,
hyperhomocysteinemia in schizophrenia seems to be linked
to vitamin B12 deficiency, likely caused by a lack of dietary
animals proteins [22]. Results of Kim and Moon [24]
showed that Korean schizophrenic patients with high serum
Table 2 Changes of the total level of homocysteine and the level of selected biomarkers of oxidative stress in plasma of healthy subjects and
schizophrenic patients
The total level
of homocysteine
(lM)
The level of carbonyl
groups in plasma proteins
(nmol carbonyl groups/mg
of plasma proteins)
The level of 3-nitrotyrosine
in plasma proteins
(nmol 3-nitrotyrosine/mg
of plasma proteins)
The level of TBARS
(nmol TBARS/ml
of plasma)
Healthy subjects 6.163 ± 0.508 0.178 ± 0.017 0.0075 ± 0.0013 1.109 ± 0.083
Schizophrenic patients 13.010 ± 1.082
(P = 1.96 9 10-6)
0.482 ± 0.065
(P = 3.1 9 10-4)
0.044 ± 0.0072
(P = 3.6 9 10-6)
1.655 ± 0.105
(P = 1.6 9 10-4)
The results are representative of independent experiments in triplicate and expressed as a mean ± SD. The statistical analysis of difference
between the tested groups was done using Mann–Whitney test
Fig. 1 The correlation between the selected parameters of oxidative
stress [the level of carbonyl groups (a), the level of 3-nitrotyrosine
(b), the level of TBARS (c)] and the total level of homocysteine in
plasma obtained from schizophrenic patients. Regression line was
calculated by means of the least-squares method
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homocysteine levels may have the genetic defect of having
low folate serum levels.
Increased concentration of homocysteine in the blood
may not only be an independent risk factor for atheroscle-
rotic disease, deep vein thrombosis and thromboembolism,
and may promote also cerebrovascular diseases. Bleich et al.
[26] and Sachdev et al. [27] showed a significant positive
relationship between plasma homocysteine levels and brain
atrophy. Brown et al. [28] suggest that elevated third-tri-
mester homocysteine levels may increase schizophrenia risk
through developmental effects on brain structure and func-
tion and/or through subtle damage to the placental vascula-
ture that compromises oxygen delivery to the fetus. Results
of Song et al. [29] showed that homocysteine metabolism
and monoaminergic neurotransmitter systems are important
in schizophrenia pathology. They hypothesized that the gene
PNPO (pyridoxine 50-phosphatase oxidase gene) might be a
candidate for susceptibility to schizophrenia because PNPO
encodes pyridoxamine 50-phosphate oxidase (EC 1.4.3.5), a
rate-limiting enzyme in pyridoxal 50-phosphate (PLP, vita-
min B(6)) synthesis. PLP is a metabolically-active form of
vitamin B(6) and thus, is required as a co-factor for enzymes
involved in both homocysteine metabolism and synthesis of
neurotransmitters such as catecholamine. Moreover, some
results suggest that association of homocysteine with
schizophrenia may involve the glutamatergic system [30–
32]. Homocysteine may act as an antagonist at the glycine
site of the NMDA receptor (in the presence of normal or low
glycine levels) or it may act as an agonist at the glutamate site
of this receptor (when glycine levels are increased) [32].
Homocysteine may also enhance oxidative stress [31, 33].
Our earlier [3, 5] and present results (Table 2) or the results
of Yao et al. [34] suggest that schizophrenia is characterized
by abnormal oxidative stress. The present study provides
more information about the mechanisms of oxidative stress
in schizophrenic patients. The first time, our results showed
that the elevated level of Hcys may play an important role in
the oxidative stress in schizophrenic patients (in an acute
period of psychosis; Fig. 1). Experiments presented here
showed that the correlation between the increased amount of
Hcys and the oxidative stress in plasma from schizophrenic
patients exists (Fig. 1). It should be underlined that in our
present study all schizophrenic patients were treated with
second-generation anti-psychotic drugs, which do not induce
the oxidative stress in different elements of blood, including
blood platelets and plasma [35, 36]. However, typical anti-
psychotic drugs (chlorpromazine) may play a role as modi-
fying factor for folate metabolism in chronic schizophrenic
patients [37], but in our present experiments patients were
treated with other antipsychotic drugs (clozapine, risperi-
done, olanzapine) during therapy. Moreover, results of
Henderson et al. [38] did not show association with second-
generation anti-psychotic drugs (clozapine, risperidone,
olanzapine) and Hcys levels in schizophrenic patients.
Experiments of Neeman et al. [39] also demonstrated that
plasma levels of amino acids, including Hcys in normal
subjects and patients treated with these drugs did not differ
significantly.
On the basis of various observations, it proposed that
diet polyphenolic antioxidants can inhibit the oxidative
stress induced by Hcys [8, 40], therefore the next step of
future studies is to evaluate the role of different antioxi-
dants in the oxidative stress in schizophrenic patients,
which have the elevated Hcys.
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